Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1930122 | Biochemical and Biophysical Research Communications | 2012 | 5 Pages |
Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC50 of 18 μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.
► Voacangine exhibits potent anti-angiogenic activity both in vitro and in vivo. ► Voacangine inhibits tumor-induced angiogenesis by suppressing HIF-1α. ► Voacangine could be the basis for the development of novel anti-angiogenic agents.